ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER
ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER
批准号:
6662970
负责人:
PAUL C VAN VELDHUISEN
金额:
$31.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-09-01 至 2004-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This is an application for 5 years of support for the coordinating center
at The EMMES Corporation to continue participation in the ongoing
multicenter Advanced Glaucoma Intervention Study (AGIS).
The principal goal of AGIS is to assess systematically the long-range
outcomes of sequences of interventions in eyes with primary open-angle
glaucoma that have failed initial medical treatment. Between April 1,
1988 and March 31, 1991 AGIS has enrolled 575 eyes of 435 patients. Each
eye has been randomly assigned to one of two intervention sequences: 1)
trabeculectomy (T) followed by argon laser trabeculoplasty (ALT) should T
fail and followed by a second T should ALT fail; and 2) ALT followed by T
should ALT fail and followed by another T should the first T fail. The
interventions are supplemented with medical treatment as needed. As of
March 31, 1991 follow-up ranged from 0 to 36 months. Less than five
percent of follow-up exams, scheduled at 6-month intervals, have been
missed. Data are being collected on visual function loss, intervention
failure, complications, need for supplemental medical therapy, compliance
with medical therapy, and quality of life. The prognostic value of
ocular and non-ocular medical factors and personal factors are being
studied. The study plans 1) to continue patient recruitment until 790
eyes are enrolled, a goal that is expected to be reached between April 1
and November 30, 1992, and 2) to continue patient follow-up until
November 30, 1996, so that follow-up will ultimately range from a minimum
of 4 to 4 2/3 years to a maximum of 8 2/3 years. The coordinating center
provides data management, statistical, and operational support to the
study. A Policy and Treatment Effects Monitoring Board supervises the
conduct of the study and monitors study outcomes. Submitted with the
Georgetown University lead application are: 1) the AGIS research plan,
detailing study rationale, design, and methods, 2) the plans for
continued patient recruitment and follow-up, and 3) study accomplishments
to date, including examples of data analyses. The present application
details the qualifications of the coordinating center for continued
participation, including a description of our accomplishments to date.
期刊论文(37)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Adenosine-mediated regulation of cyclic AMP levels in isolated incubated retinas.
腺苷介导的离体孵化视网膜中环 AMP 水平的调节。
DOI:
10.1016/0006-8993(86)91299-0
发表时间:
1986
期刊:
Brain research
影响因子:
2.9
作者:
[Blazynski,C, Kinscherf,DA, Geary,KM, Ferrendelli,JA]
通讯作者:
Ferrendelli,JA
Sandwich enzyme immunoassay and latex agglutination test for herpes simplex virus keratitis.
单纯疱疹病毒角膜炎的夹心酶联免疫分析和乳胶凝集试验。
DOI:
10.1128/jcm.28.4.785-786.1990
发表时间:
1990
期刊:
Journal of clinical microbiology
影响因子:
9.4
作者:
[Lee,SF, Pepose,JS]
通讯作者:
Pepose,JS
Herpes simplex virus type 1 transcription is not detectable in quiescent human stromal keratitis by in situ hybridization.
通过原位杂交在静止的人基质性角膜炎中检测不到单纯疱疹病毒 1 型转录。
DOI:
--
发表时间:
1993
期刊:
Investigative ophthalmology & visual science
影响因子:
4.4
作者:
[Laycock,KA, Lee,SF, Stulting,RD, Croen,KD, Ostrove,JM, Straus,SE, Pepose,JS]
通讯作者:
Pepose,JS
Kynurenic acid distinguishes kainate and quisqualate receptors in the vertebrate retina.
犬尿酸可区分脊椎动物视网膜中的红藻氨酸和使君子酸受体。
DOI:
10.1016/0006-8993(86)90708-0
发表时间:
1986
期刊:
Brain research
影响因子:
2.9
作者:
[Coleman,PA, Massey,SC, Miller,RF]
通讯作者:
Miller,RF
Effects of dopamine antagonists on receptive fields of brisk cells and directionally selective cells in the rabbit retina.
多巴胺拮抗剂对兔视网膜中活跃细胞和定向选择性细胞感受野的影响。
DOI:
10.1523/jneurosci.04-12-02972.1984
发表时间:
1984
期刊:
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子:
--
作者:
[Jensen,RJ, Daw,NW]
通讯作者:
Daw,NW
共 24 条
SCORE2 Comparative Trial (SCT)
-
批准号:8926101
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2013
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
SCORE2 Comparative Trial (SCT)
-
批准号:8992010
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2013
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
SCORE2 Comparative Trial (SCT)
-
批准号:9056428
-
项目类别:
-
资助金额:$151.86万
-
财政年份:2013
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
SCORE2 Comparative Trial (SCT)
-
批准号:8551917
-
项目类别:
-
资助金额:$143.34万
-
财政年份:2013
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
SCORE2 Comparative Trial (SCT)
-
批准号:8737268
-
项目类别:
-
资助金额:$126.71万
-
财政年份:2013
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
DATA AND STATISTICS CENTER FOR THE NIDA CLINICAL TRIALS NETWORK
-
批准号:7952690
-
项目类别:
-
资助金额:$98.92万
-
财政年份:2009
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
DATA AND STATISTICS CENTER FOR THE NIDA CLINICAL TRIALS NETWORK
-
批准号:8008922
-
项目类别:
-
资助金额:$329.85万
-
财政年份:2009
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:6901852
-
项目类别:
-
资助金额:$92.39万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:7077671
-
项目类别:
-
资助金额:$12.73万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:6556994
-
项目类别:
-
资助金额:$62.72万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:6928233
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:6743961
-
项目类别:
-
资助金额:$61.61万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
Intravitreal Corticosteroid for Macular Edema
-
批准号:7616936
-
项目类别:
-
资助金额:$127.06万
-
财政年份:2003
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER
-
批准号:2888295
-
项目类别:
-
资助金额:$62.64万
-
财政年份:1987
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER
-
批准号:6178946
-
项目类别:
-
资助金额:$54.27万
-
财政年份:1987
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER
-
批准号:6384575
-
项目类别:
-
资助金额:$18.11万
-
财政年份:1987
-
负责人:PAUL C VAN VELDHUISEN
-
依托单位:
海外基金